1093819-56-7

Basic information

• Product Name: N-(2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide
• Synonyms: N-(2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide
• CAS NO: 1093819-56-7
• Molecular Weight: 430.668
• Mol File: 1093819-56-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-(2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(1093819-56-7)
• EPA Substance Registry System: N-(2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide(1093819-56-7)

Safety Data

• Hazardous Substances Data: 1093819-56-7(Hazardous Substances Data)

Upstream product

• 73183-34-3 bis(pinacol)diborane 
• 1073354-96-7 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine 
• 13918-92-8 2,4-difluorobenzene-1-sulfonyl chloride 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 588729-99-1 3-amino-5-bromo-2-chloropyridine 
• 15862-34-7 5-bromo-3-nitro-1H-pyridin-2-one 
• 1083326-21-9 N-(5-bromo-2-chloropyridin-3-yl )-2,4-difluorobenzenesulfonamide 

Downstream Products

• 1400667-73-3 N-(2-chloro-5-(4-(tetrahydro-2H-pyran-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400667-76-6 N-(2-chloro-5-(4-(1-methylpiperidin-4-yloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400667-93-7 N-(2-chloro-5-(4-(cyclopentyloxy)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluoro benzenesulfonamide 
• 1400667-94-8 N-(2-chloro-5-(4-(tetrahydro-2H-pyran-4-ylamino)pyrido[3,2-d]pyrimidin-6-yl)-pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400667-95-9 N-(2-chloro-5-(4-(cyclopentylamino)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluoro benzenesulfonamide 
• 1400667-96-0 N-(2-chloro-5-(4-(cyclobutylamino)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluoro benzenesulfonamide 
• 1400667-97-1 N-(2-chloro-5-(4-(cyclopropylamino)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluoro benzenesulfonamide 
• 1400668-00-9 N-(2-chloro-5-(4-(4-(trifluoromethoxy)phenylamino)pyrido[3,2-d]pyrimidin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1400668-01-0 tert-butyl 4-(6-(6-chloro-5-(2,4-difluorophenylsulfonamido)pyridin-3-yl)pyrido[3,2-d]pyrimidin-4-ylamino)piperidine-1-carboxylate 
• 1551453-75-8 N-(2-chloro-5-(4-(3-hydroxyprop-1-yn-1-yl)quinolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1551453-78-1 N-(2-chloro-5-(4-(3-hydroxybut-1-yn-1-yl)quinolin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1567836-89-8 2,4-difluoro-N-(2-chloro-5-(5-(2-methyl-1-oxoisoindolin-5-yl)thiophen-2-yl)pyridin-3-yl)benzenesulphonamide 
• 1621718-41-9 N-(2-chloro-5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 

Relevant articles and documents

Micro-reactor tandem synthesis method of indole anticancer drug molecules

The invention relates to a micro-reactor tandem synthesis method of indole anticancer drug molecules. The method comprises the following steps: a reaction liquid 1 and a reaction liquid 2 are mixed, then are introduced into a first micro-reactor, and are reacted to obtain a first effluent, the first effluent and a reaction liquid 3 are mixed, then are introduced into a second micro-reactor, and are reacted to obtain a second effluent, the second effluent and a reaction liquid 4 are mixed, then are introduced into a third micro-reactor, and are reacted to obtain a final effluent, and the finaleffluent is concentrated and separated to obtain the indole anticancer drug molecules, wherein the reaction liquid 1 is a mixed solution containing 5-bromine-3-amino-2-substituted (R1)-pyridine, the reaction liquid 2 is substituted (R2)-benzenesulfonyl chloride, the reaction liquid 3 is a mixed solution containing bis(pinacolato)diboron, the reaction liquid 4 is a mixed solution containing a 5-bromo-7-azaindole derivative, and the indole anticancer drug molecules are benzenesulfonamidopyridylazaindole compounds. Compared with the prior art, the method of the invention has the advantages of high reaction efficiency, few side reactions and simple production process.

Substituted arylsulphonamides as inhibitors of perforin-mediated lysis

The structure-activity relationships for a series of arylsulphonamide-based inhibitors of the pore-forming protein perforin have been explored. Perforin is a key component of the human immune response, however inappropriate activity has also been implicated in certain auto-immune and therapy-induced conditions such as allograft rejection and graft versus host disease. Since perforin is expressed exclusively by cells of the immune system, inhibition of this protein would be a highly selective strategy for the immunosuppressive treatment of these disorders. Compounds from this series were demonstrated to be potent inhibitors of the lytic action of both isolated recombinant perforin and perforin secreted by natural killer cells in vitro. Several potent and soluble examples were assessed for in vivo pharmacokinetic properties and found to be suitable for progression to an in vivo model of transplant rejection.

PI3 KINASE MODULATORS AND METHODS OF USE

This invention relates to the field of lipid kinases and modulators thereof. In particular, the invention relates to modulators of phosphatidylinositol 3-kinases (PI3 kinases or PBKs) signaling pathways, and methods of their use. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in modulating of PI3K signaling pathways and their related disorders in mammals, especially humans.